Information concerning the negative impact on the right to health and other human rights resulting from responses by pharmaceutical companies to U.S. sanctions against Iran. Specifically, I have received information that a subsidiary of the Swiss company Novartis AG (Novartis) has stopped providing at least some vital medications for Iranians suffering from thalassemia, and the French company Roquette Frères (Roquette) has stopped providing to Iran the ingredients it produces for making medicines used in treating thalassemia, following the re-imposition and expansion of U.S. sanctions against Iran since 2018, even though the sanctions permit the continued sale to Iran of products of a humanitarian nature.